Follow

RLS Global: The rights issue is registered and the trading in Paid Subscription Shares ceases

09 December 2022 - 09:00

RLS Global AB (publ) (”RLS Global” or "the Company”) has completed a rights issue of shares that closed on 11 November, 2022. The rights issue is now registered with the Swedish Companies Registration Office and the last day for trading in paid subscribed shares ("BTA") will be Wednesday, December 14th, 2022. The record date will be December 16th, 2022, after which the BTAs are converted into ordinary shares on Tuesday December 20th, 2022.

The information was submitted for publication, through the agency of the contact persons set out below, on December 9th, 09.00 CEST.

TRADING PLACE AND CERTIFIED ADVISER:
RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag. During the period 2012–2017, the company was listed on Aktietorget.

FOR MORE INFORMATION, PLEASE CONTACT:
Björn Larsson, CEO, RLS Global
E-mail: [email protected]
Tel: +46 766 20 17 25

ABOUT RLS GLOBAL:
RLS Global AB is a medical technology company within Life Science. Based on the company's unique hypochlorite platform, RLS develops and sells products under the brand ChloraSolv® for indications within advanced wound care.
RLS's long-term vision is to be a leading research-driven platform company in wound care. The ambition is to expand to new indications through new research and development projects in areas such as burns and dermatology. To maximize market presence, RLS works with partners to commercialize products globally. RLS is convinced that the company's platform technology and its unique features will help many patients around the world. Read more at www.rls.global

Provided by: Cision
Nasdaq First North GM Stockholm (Sweden)
RLS Global AB
RLS Global develops and sells biochemical products for the treatment of some of common diseases in wound and dental care....
Learn more about company

Related news

We use cookies to make your experience using IPOhub better. By using our site you agree to our use of cookies. Learn More